Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: mannitol; titanium dioxide; diacetylated monoglycerides; crospovidone; hypromellose phthalate; light magnesium oxide; ethylcellulose; hyprolose; magnesium stearate; purified talc; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; titanium dioxide; mannitol; crospovidone; magnesium stearate; iron oxide yellow; diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; purified talc; hyprolose; hypromellose phthalate - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ciprofloxacin hydrochloride, quantity: 294.586 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 556 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism; moderately severe/severe androgen dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyrotone inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused by either increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if cyrotone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male fetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation. men: reduction of drive in sexual deviations. cyrotone reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. cyrotone should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period to reduced drive for personal and social reorientation. inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.